Equities Analysts Set Expectations for BrainsWay Q3 Earnings

BrainsWay Ltd. (NASDAQ:BWAY - Free Report) - HC Wainwright cut their Q3 2024 EPS estimates for BrainsWay in a research report issued on Monday, October 21st. HC Wainwright analyst R. Selvaraju now anticipates that the company will earn $0.02 per share for the quarter, down from their previous estimate of $0.04. HC Wainwright has a "Buy" rating and a $16.00 price target on the stock. The consensus estimate for BrainsWay's current full-year earnings is $0.06 per share. HC Wainwright also issued estimates for BrainsWay's Q4 2024 earnings at $0.02 EPS and FY2024 earnings at $0.06 EPS.

BrainsWay (NASDAQ:BWAY - Get Free Report) last announced its quarterly earnings data on Tuesday, August 6th. The company reported $0.04 earnings per share (EPS) for the quarter. The business had revenue of $10.01 million for the quarter, compared to analysts' expectations of $9.40 million. BrainsWay had a return on equity of 1.45% and a net margin of 1.67%. During the same period in the previous year, the business posted ($0.05) EPS.

Separately, Northland Securities boosted their target price on shares of BrainsWay from $11.00 to $12.50 and gave the company an "outperform" rating in a report on Thursday, October 3rd.

BrainsWay Trading Down 0.2 %

Shares of BWAY stock traded down $0.02 during trading on Tuesday, reaching $9.92. 38,487 shares of the company's stock traded hands, compared to its average volume of 96,470. The firm's 50-day moving average is $8.47 and its 200 day moving average is $6.90. The company has a market capitalization of $165.32 million, a P/E ratio of -110.22 and a beta of 1.26. BrainsWay has a 1 year low of $3.09 and a 1 year high of $10.61.

Institutional Investors Weigh In On BrainsWay

A number of institutional investors and hedge funds have recently modified their holdings of the company. Virtu Financial LLC bought a new stake in BrainsWay during the first quarter valued at $60,000. Quadrature Capital Ltd bought a new stake in shares of BrainsWay during the 4th quarter valued at about $70,000. Rhumbline Advisers grew its holdings in shares of BrainsWay by 10.3% during the second quarter. Rhumbline Advisers now owns 18,077 shares of the company's stock worth $110,000 after purchasing an additional 1,695 shares in the last quarter. Perritt Capital Management Inc bought a new position in shares of BrainsWay in the second quarter worth approximately $121,000. Finally, Good Life Advisors LLC raised its stake in BrainsWay by 65.5% in the third quarter. Good Life Advisors LLC now owns 55,800 shares of the company's stock valued at $516,000 after purchasing an additional 22,080 shares in the last quarter. 30.11% of the stock is owned by hedge funds and other institutional investors.

BrainsWay Company Profile

BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases.